Active surveillance of carbapenem-resistant Gram-negative healthcare-associated infections in a low-middle-income country city

被引:5
|
作者
Carvalho Hessel Dias, Viviane Maria de [1 ]
da Silva, Daniela Maria Waszak [2 ]
Burger, Marion [1 ,2 ]
de Oliveira, Alcides Augusto Souto [2 ]
Capelo, Patricia de Jesus [3 ]
Rocha Specian, Fabio Augusto da [1 ]
de Figueiredo, Marianna Cavina [1 ]
Tuon, Felipe Francisco [1 ]
Baena, Cristina Pellegrino [1 ]
机构
[1] Pontificia Univ Catolica Parana, Escola Med, Curitiba, Parana, Brazil
[2] Secretaria Municipal Saude Curitiba, Curitiba, Parana, Brazil
[3] Secretaria Saude Estado Parana, Curitiba, Parana, Brazil
来源
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES | 2021年 / 25卷 / 02期
关键词
Healthcare-associated infections; Carbapenem resistance; Active surveillance; Low-middle-income countries; MOLECULAR EPIDEMIOLOGY; ACINETOBACTER-BAUMANNII; HOSPITALS; ENTEROBACTERIACEAE; PREVENTION; BACTERIA;
D O I
10.1016/j.bjid.2021.101540
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Carbapenem-resistance in healthcare-associated infections (HCAIs) is of great concern, and it is urgent to improve surveillance. We aimed to describe and analyze HCAIs trends on Gram-negative antimicrobial susceptibility in a city from a developing country, following the implementation of an active surveillance program. Methods: This is an aggregated study describing data from 24 hospitals with intensive care units, including a trend analysis by Joinpoint regression between January 2012 and December 2017. Results: There were 23,578 pathogens in 39,832 HCAIs, from which 16,225 were Gramnegatives (68.8%). Carbapenem susceptibility was lowest in A. baumannii (15.4-25.9%), K. pneumoniae (51.0-55.9%), and P. aeruginosa (64.9-84.1%) and highest in E. coli (96.5-99.2%). Only K. pneumoniae showed a significant Joinpoint at 95% confidence interval: -10.71% (-18.02; -2.75) from 2012 to 2014, p = 0.02, and 6.54% (-2.00; 15.83) from 2015 to 2017, p = 0.12, which was most influenced by urinary tract infections: -9.98% (-16.02; -3.48) from 2012 to 2014, p = 0.01, and 9.66% (-1.75; 22.39) from 2015 to 2017, p = 0.09. Conclusion: Although we found a significant change toward an improvement in carbapenem susceptibility in K. pneumoniae, resistance is high for most pathogens. These data should encourage health institutions to improve their prevention and control strategies. (C) 2021 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U.
引用
收藏
页数:7
相关论文
共 50 条
  • [22] Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections
    G. L. Xia
    R. L. Jiang
    BMC Infectious Diseases, 21
  • [23] Evidence to improve the treatment of infections caused by carbapenem-resistant Gram-negative bacteria
    Perez, Federico
    Bonomo, Robert A.
    LANCET INFECTIOUS DISEASES, 2018, 18 (04): : 358 - 360
  • [24] Predictors of Mortality in Patients with Infections Due to Carbapenem-Resistant Gram-Negative Bacteria
    Rivera-Villegas, Hector Orlando
    Martinez-Guerra, Bernardo Alfonso
    Garcia-Couturier, Rosalia
    Xancal-Salvador, Luis Fernando
    Esteban-Kenel, Veronica
    Jaimes-Aquino, Ricardo Antonio
    Mendoza-Rojas, Miguel
    Cervantes-Sanchez, Axel
    Mendez-Ramos, Steven
    Alonso-Montoya, Jorge Eduardo
    Munguia-Ramos, Diana
    Tamez-Torres, Karla Maria
    Roman-Montes, Carla Marina
    Rajme-Lopez, Sandra
    Martinez-Gamboa, Areli
    Bobadilla-del-Valle, Miriam
    Gonzalez-Lara, Maria Fernanda
    Sifuentes-Osornio, Jose
    Ponce-de-Leon, Alfredo
    ANTIBIOTICS-BASEL, 2023, 12 (07):
  • [25] Adaptive trials of new antimicrobials for infections with carbapenem-resistant, Gram-negative bacteria
    Gatti, Milo
    Giannella, Maddalena
    Scudeller, Luigia
    Viale, Pierluigi
    LANCET INFECTIOUS DISEASES, 2020, 20 (01): : 24 - 24
  • [26] Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections
    Victoria Gavaghan
    Jessica L. Miller
    Jennifer Dela-Pena
    Infection, 2023, 51 : 475 - 482
  • [27] Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections
    Xia, G. L.
    Jiang, R. L.
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [28] Carbapenem Consumption and Rate of carbapenem-resistant gram-negative bacteria: results from the Sicilian Surveillance System
    Barchitta, M.
    Maugeri, A.
    La Rosa, M. C.
    La Mastra, C.
    Murolo, G.
    Basile, G.
    Agodi, A.
    ANNALI DI IGIENE MEDICINA PREVENTIVA E DI COMUNITA, 2021, 33 (03): : 289 - 296
  • [29] Using Molecular Diagnostics to Develop Therapeutic Strategies for Carbapenem-Resistant Gram-Negative Infections
    Tenover, Fred C.
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2021, 11
  • [30] Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens
    Cruz-Lopez, Flora
    Martinez-Melendez, Adrian
    Morfin-Otero, Rayo
    Rodriguez-Noriega, Eduardo
    Maldonado-Garza, Hector J.
    Garza-Gonzalez, Elvira
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12